Navigation Links
Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
Date:4/14/2008

HAYWARD, Calif., April 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that the Phase 2 trial of epothilone KOS-1584 in patients with non-small cell lung cancer has been initiated. The Phase 2 trial is an open-label, multi-center, monotherapy study of KOS-1584 in patients with measurable advanced or metastatic non-small cell lung cancer who have previously received only one prior chemotherapy regimen. The primary endpoint of the Phase 2 trial is objective response rate. Secondary endpoints include progression-free survival, time to progression, time to treatment failure, time to response, duration of response and overall survival. KOS-1584 will be administered via a 3-hour intravenous infusion weekly for two weeks out of every three weeks at a dose of 25 mg/m(2). The Phase 2 trial will enroll up to 50 patients in a two-stage Simon design.

"We have been impressed by the breadth and level of activity and tolerability we have observed with KOS-1584 in our Phase 1 trials and believe that KOS-1584 has competitive potential in the emerging epothilone class of anticancer agents," said Helen S. Kim, Kosan's President and Chief Executive Officer. "Kosan's epothilone strategy is to advance KOS-1584 to its next inflection point while seeking a corporate partner to conduct a registration program and advance our preclinical product candidate, KOS-1803, into clinical development. We believe that KOS-1584's therapeutic profile and potential for near-term commercialization enhance its value for potential pharmaceutical collaborators."

KOS-1584 is a member of a class of cytotoxic macrolides (epothilones) capable of causing mitotic arrest by polymerization of cellular microtubules. Since microtubules
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
2. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
3. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
6. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
7. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
8. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
9. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
10. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
11. Metabolex Initiates Phase 1 Trial of MBX-2982
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/10/2014)... 2014  Major advances in radiation therapy and ... highlighted in a three-day Oncology Summit taking place ... 2014.  Renowned national and international cancer experts from seven ... exchange knowledge on modern technologies making treatment for ... The Summit will address a wide ...
(Date:7/10/2014)... 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... analog IC solutions, today announced that it will host ... at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) ... 2014 third quarter ended June 30, 2014. ... before 6:50 a.m. Pacific time on July 24, 2014.  ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... DENVER, Nov. 12 Corgenix Medical Corporation (OTC Bulletin Board: ... today reported sales of $2,044,967 for the first fiscal quarter ... ended September 30, 2008, an increase of 2.2%. , The ... compared with an operating loss of $94,133 for the first ...
... WASHINGTON, Nov. 12 Women,s Health Weekly recently ... are working on nearly 1,000 life-changing medicines for diseases affecting ... the Pharmaceutical Research and Manufacturers of America ... Food and Drug Administration or are in human clinical trials. ...
Cached Medicine Technology:Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3Record Number of New Medicines in Development for Women 2
(Date:7/11/2014)... (PRWEB) July 11, 2014 Utilizing the ... own, Dr. William Koenig, has topped a record number ... he has performed over 400 successful procedures without the ... Koenig is well known across the country for his ... safety record has long been the foundation for numerous ...
(Date:7/11/2014)... News) -- Children who have emergency surgery on ... potentially even death than those who have weekday ... the Johns Hopkins researchers noted that the risk ... data on nearly 440,000 simple emergency surgeries that ... 22-year period. The surgeries are considered generally ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional Foods, ... Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, Bifidobacteria, ... ” defines and segments the global probiotics market ... value of probiotic products and ingredients. The report ... the global market with an analysis of trends, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Global enterprises ... services to outsource day-to-day management activities. Managed services offer ... additional expenses. The economic slowdown resulted into rising operational ... and expenses is considered to be the global market ... future. , The global managed services market is estimated ...
(Date:7/11/2014)... As reported by the New York ... significant number of severe adverse events such as renal ... death from the highly-promoted and costly immune-system drug, Acthar, ... report , a regulatory filing revealed that the total ... almost 14% of prescriptions, up from 9.1% in 2011. ...
Breaking Medicine News(10 mins):Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3
... , SUNDAY, June 5 (HealthDay News) -- The human ... that stores calories and the "good" brown kind that burns ... make more brown fat to help people lose weight. ... be used for treating obesity and diabetes," study lead author ...
... -- ASCO Abstract #CRA9015. Flaxseed provides no benefit in ... and postmenopausal women, according to a Mayo Clinic ... (NCCTG) study. The randomized, placebo-controlled study was conducted on ... no statistically significant difference in mean hot flash scores ...
... children who had cancer, with follow-up of about 25 years, ... (a new tumor) at older than age 40 years was ... urinary tract organs), according to a study in the June ... cancer. The study is being published early online to coincide ...
... that the worse a woman,s skin wrinkles are during the ... is. The results will be presented Monday at The Endocrine ... the appearance of the skin may offer a glimpse of ... Pal, MD, a reproductive endocrinologist and associate professor at Yale ...
... , FRIDAY, June 3 (HealthDay News) -- U.S. health officials ... the deadly new strain of E. coli bacteria affecting Germany ... "This outbreak has not affected the U.S.," David ... Operations, said during a Friday afternoon news conference. ...
... mutant gene long thought to accelerate tumor growth in ... cells, showing promise for novel cancer therapies, a Mayo ... presented by Mayo Clinic researcher Honey Reddi, Ph.D., at ... discovery could have widespread implications in cancer research and ...
Cached Medicine News:Health News:Brown Fat Cells May One Day Help Combat Obesity 2Health News:Mayo Clinic: Flaxseed no cure for hot flashes during breast cancer or menopause 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 3Health News:Severity of facial wrinkles may predict bone density in early menopause 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 3Health News:Fighting cancer with cancer: Mayo Clinic finds promising use for thyroid cancer gene 2